You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 196111 - 196120 of 207731 results
  1. Topic 2 Subtopic a Title: Accelerated Deployment of MFEM Based Solvers in Large Scale Industrial Problems

    SBC: RELOGIC RESEARCH, INC.            Topic: C5302a

    While many Advanced Scientific Computing Research (ASCR) supported software packages are open source, they are often complicated to use, distributed primarily in source-code form targeting HPC systems, and potential adopters lack options for purchasing commercial support, training, and custom- development services. In response to this need, ReLogic Research, Inc., in collaboration with Lawrence Li ...

    SBIR Phase I 2022 Department of Energy
  2. TOPIC 385: SURVIVORCARE: A DIGITAL HEALTH SOLUTION TO SUPPORT LONG-TERM CANCER SURVIVORSHIP USING PATIENT NAVIGATION- MOONSHOT

    SBC: DIMAGI, INC.            Topic: NCI

    The overall objective of this Phase I SBIR project is to study the feasibility and acceptability of SurvivorCarea mobileand web based system to support long term cancer survivorship through patient navigation for low incomeunderserved populationsFollowing a user centered design approachthe contractor will develop a tool expressly designed for patient navigatorsPNsand colorectal cancer survivors to ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Topic 374: Sustained Delivery of PARP Inhibitors for Cancer Chemoprevention

    SBC: TheraNano LLC            Topic: NCI

    Here we propose to study two injectable formulations that provide different delivery routes for Talazoparib, potent PAPR inhibitor: An implant, InCeT-Talazoparib, which can be injected directly in the tumor where it will act as a sustained release depot of Talazoparib over a prolonged period of approximately 30 days. It delivers 100% of the drug to the tumor site with almost no systemic toxicity. ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Topic 377: Symptom Management and Intervention Roadmaps (STaIRS)

    SBC: CAREVIVE SYSTEMS INC            Topic: NCI

    Numerous adverse symptoms are under-detected in cancer care resulting1-3 in missed opportunities for intervention; leading to poor treatment adherence, avoidable hospitalizations, and worse morbidity and survival. The IOM proposed shaking up the current symptom paradigm from reactive to proactive, personalized, technology-enabled models of symptom care as a solution to this clinical quality crisis ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. TOPIC 377: SYMPTOM MANAGEMENT AND INTERVENTION ROADMAPS (STAIRS) (MOONSHOT) PHASE II

    SBC: CAREVIVE SYSTEMS INC            Topic: 377

    Numerous adverse symptoms are under-detected in cancer care resulting1-3 in missed opportunities for intervention; leading to poor treatment adherence, avoidable hospitalizations, and worse morbidity and survival. The IOM proposed shaking up the current symptom paradigm from reactive to proactive, personalized, technology-enabled models of symptom care as a solution to this clinical quality crisis ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  6. TOPIC 414: SYNTHETIC BIOLOGY GENE CIRCUITS FOR CANCER THERAPY

    SBC: Strand Therapeutics Inc.            Topic: 414

    B-cell non-Hodgkin’s lymphoma (NHL) is the most common hematological malignancy derived from B-cells and expresses high levels of the CD19 antigen. Although past gene therapy efforts that target CD19, such as chimeric antigen T cell receptor (CAR-T) immunotherapy, have demonstrated immense clinical benefit, manufacturing challenges and toxicity have significantly limited its utility. To this end ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  7. TOPIC 414: SYNTHETIC BIOLOGY GENE CIRCUITS FOR CANCER THERAPY

    SBC: Senti Biosciences, Inc.            Topic: 414

    The therapeutic administration of chimeric antigen receptor (CAR)-based cell therapies has considerably advanced the treatment of certain cancers. Unfortunately, the successes of CAR-based cell therapies have not yet translated to treatment of acute myeloid leukemia (AML), likely due to the lack of a suitable lineage antigen target. Due to their nonrestrictive expression, most AML antigens are als ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  8. Topic 364: SysMet: Integrative Systems Metabolomics

    SBC: OMICSCRAFT LLC            Topic: NCI

    Metabolomics plays an indispensable role in the growing systems biology approaches to identify reliable cancer biomarkers. Liquid chromatography coupled to mass spectrometry (LC-MS) and gas chromatography coupled to mass spectrometry (GC-MS) have been extensively used for high-throughput comparison of the levels of thousands of metabolites among biological samples. However, the potential values of ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Topic 374: Targeted and Sustained Release Microparticles for Colon Cancer Chemoprevention

    SBC: ZYMERON CORPORATION            Topic: NCI

    Colorectal Cancer (CRC) is the third most common cancer both in men and women, as well as the second leading cause of cancer deaths with an estimated 135,430 new cases diagnosed and 50,260 deaths for 2017 in the United States. Given the limitations of screening tests and poor prognosis associated with advanced stage colorectal cancer, it would be of great interest in exploring chemoprevention stra ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Topic 346: Targeted Radionuclide Therapy of Neuroendocrine Tumors Using 212Pb-octreotate Analogs

    SBC: RADIOMEDIX, INC.            Topic: NCI

    A peptide receptor radionuclide therapy (PRRT) using [177Lu]/[90Y]-labeled somatostatin analogs has been proven to induce objective response in 30-45% of patients with advanced/progressive neuroendocrine tumors (NETs). The complete response to beta-emitter PRRT is rare. This is due to the fact that NETs are diagnosed at late stage of disease; the NETs patients with remissions could develop resista ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government